Pharmacological evidence that serotonergic stimulation of prolactin secretion is mediated via the dorsal raphe nucleus

Louis D. van de Kar, Cynthia Bethea

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Administration of the serotonin-releasing drug DL-p-chloroamphetamine (PCA) to rats caused a dose-dependent increase in plasma prolactin levels. The effect was maximal 2 h after administration. The effect of PCA was prevented by prior administration of the serotonin synthesis inhibitor p-chlorophenylalanine-methyl ester (PCPA). PCPA pre-treatment did not prevent the increase in plasma prolactin levels after administration of the serotonin agonist quipazine which is consistent with a postsynaptic receptor interaction of quipazine. To determine which serotonergic neurons are involved, the prolactin responses to PCA were determined in rats sustaining lesions of the dorsal or median raphe nuclei. The lesions were produced in desmethylimipramine-pretreated rats by local injections of 5,7-dihydroxytryptamine (5,7-DHT) 2 weeks prior to the PCA challenge. In rats with dorsal raphe lesions, the effect of PCA on prolactin secretion was significantly attenuated. In contrast, median raphe lesions did not prevent the effect of PCA on plasma prolactin levels. In summary, these data support the hypothesis that release of serotonin increases prolactin secretion. In addition, these data suggest that serotonergic neurons in the dorsal raphe nucleus are part of a neural pathway which can mediate increases in prolactin secretion.

Original languageEnglish (US)
Pages (from-to)225-230
Number of pages6
JournalNeuroendocrinology
Volume35
Issue number4
DOIs
StatePublished - 1982
Externally publishedYes

Fingerprint

p-Chloroamphetamine
Prolactin
Pharmacology
Quipazine
Serotonergic Neurons
Serotonin
5,7-Dihydroxytryptamine
Serotonin Agents
Neural Pathways
Serotonin Receptor Agonists
Desipramine
Raphe Nuclei
Dorsal Raphe Nucleus
Injections

Keywords

  • 5,7-dihydroxytryptamine
  • Dorsal raphe nucleus
  • Parachloroamphetamine
  • Prolactin
  • Serotonin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Cellular and Molecular Neuroscience
  • Endocrine and Autonomic Systems
  • Neuroscience(all)

Cite this

Pharmacological evidence that serotonergic stimulation of prolactin secretion is mediated via the dorsal raphe nucleus. / van de Kar, Louis D.; Bethea, Cynthia.

In: Neuroendocrinology, Vol. 35, No. 4, 1982, p. 225-230.

Research output: Contribution to journalArticle

@article{9403e3f113ef429995e6c10a5c6969c0,
title = "Pharmacological evidence that serotonergic stimulation of prolactin secretion is mediated via the dorsal raphe nucleus",
abstract = "Administration of the serotonin-releasing drug DL-p-chloroamphetamine (PCA) to rats caused a dose-dependent increase in plasma prolactin levels. The effect was maximal 2 h after administration. The effect of PCA was prevented by prior administration of the serotonin synthesis inhibitor p-chlorophenylalanine-methyl ester (PCPA). PCPA pre-treatment did not prevent the increase in plasma prolactin levels after administration of the serotonin agonist quipazine which is consistent with a postsynaptic receptor interaction of quipazine. To determine which serotonergic neurons are involved, the prolactin responses to PCA were determined in rats sustaining lesions of the dorsal or median raphe nuclei. The lesions were produced in desmethylimipramine-pretreated rats by local injections of 5,7-dihydroxytryptamine (5,7-DHT) 2 weeks prior to the PCA challenge. In rats with dorsal raphe lesions, the effect of PCA on prolactin secretion was significantly attenuated. In contrast, median raphe lesions did not prevent the effect of PCA on plasma prolactin levels. In summary, these data support the hypothesis that release of serotonin increases prolactin secretion. In addition, these data suggest that serotonergic neurons in the dorsal raphe nucleus are part of a neural pathway which can mediate increases in prolactin secretion.",
keywords = "5,7-dihydroxytryptamine, Dorsal raphe nucleus, Parachloroamphetamine, Prolactin, Serotonin",
author = "{van de Kar}, {Louis D.} and Cynthia Bethea",
year = "1982",
doi = "10.1159/000123386",
language = "English (US)",
volume = "35",
pages = "225--230",
journal = "Neuroendocrinology",
issn = "0028-3835",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Pharmacological evidence that serotonergic stimulation of prolactin secretion is mediated via the dorsal raphe nucleus

AU - van de Kar, Louis D.

AU - Bethea, Cynthia

PY - 1982

Y1 - 1982

N2 - Administration of the serotonin-releasing drug DL-p-chloroamphetamine (PCA) to rats caused a dose-dependent increase in plasma prolactin levels. The effect was maximal 2 h after administration. The effect of PCA was prevented by prior administration of the serotonin synthesis inhibitor p-chlorophenylalanine-methyl ester (PCPA). PCPA pre-treatment did not prevent the increase in plasma prolactin levels after administration of the serotonin agonist quipazine which is consistent with a postsynaptic receptor interaction of quipazine. To determine which serotonergic neurons are involved, the prolactin responses to PCA were determined in rats sustaining lesions of the dorsal or median raphe nuclei. The lesions were produced in desmethylimipramine-pretreated rats by local injections of 5,7-dihydroxytryptamine (5,7-DHT) 2 weeks prior to the PCA challenge. In rats with dorsal raphe lesions, the effect of PCA on prolactin secretion was significantly attenuated. In contrast, median raphe lesions did not prevent the effect of PCA on plasma prolactin levels. In summary, these data support the hypothesis that release of serotonin increases prolactin secretion. In addition, these data suggest that serotonergic neurons in the dorsal raphe nucleus are part of a neural pathway which can mediate increases in prolactin secretion.

AB - Administration of the serotonin-releasing drug DL-p-chloroamphetamine (PCA) to rats caused a dose-dependent increase in plasma prolactin levels. The effect was maximal 2 h after administration. The effect of PCA was prevented by prior administration of the serotonin synthesis inhibitor p-chlorophenylalanine-methyl ester (PCPA). PCPA pre-treatment did not prevent the increase in plasma prolactin levels after administration of the serotonin agonist quipazine which is consistent with a postsynaptic receptor interaction of quipazine. To determine which serotonergic neurons are involved, the prolactin responses to PCA were determined in rats sustaining lesions of the dorsal or median raphe nuclei. The lesions were produced in desmethylimipramine-pretreated rats by local injections of 5,7-dihydroxytryptamine (5,7-DHT) 2 weeks prior to the PCA challenge. In rats with dorsal raphe lesions, the effect of PCA on prolactin secretion was significantly attenuated. In contrast, median raphe lesions did not prevent the effect of PCA on plasma prolactin levels. In summary, these data support the hypothesis that release of serotonin increases prolactin secretion. In addition, these data suggest that serotonergic neurons in the dorsal raphe nucleus are part of a neural pathway which can mediate increases in prolactin secretion.

KW - 5,7-dihydroxytryptamine

KW - Dorsal raphe nucleus

KW - Parachloroamphetamine

KW - Prolactin

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=0019961782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019961782&partnerID=8YFLogxK

U2 - 10.1159/000123386

DO - 10.1159/000123386

M3 - Article

C2 - 7145018

AN - SCOPUS:0019961782

VL - 35

SP - 225

EP - 230

JO - Neuroendocrinology

JF - Neuroendocrinology

SN - 0028-3835

IS - 4

ER -